Picture [iito] Life Science Business Portals Media Data 2022 650x100px
Document › Details

Santhera Pharmaceuticals Holding AG. (1/24/20). "Press Release: Santhera Appoints New Chief Financial Officer". Pratteln.

Organisations Organisation Santhera Pharmaceuticals Holding AG (SIX: SANN)
  Group Santhera (Group)
  Organisation 2 Allecra Therapeutics GmbH
  Group Allecra Therapeutics (Group)
Products Product Raxone®
  Product 2 Puldysa®
Persons Person Smith, Andrew (Santhera 202004– CFO before Allecra Therapeutics + Sucampo Pharmaceuticals)
  Person 2 Eklund, Dario (Santhera 201912– CEO before Vifor Pharma + Organogenesis + Novartis + Sanofi)

Santhera Pharmaceuticals (SIX: SANN) announces the appointment of Andrew Smith as CFO and a member of the Executive Management team, effective April 1, 2020.

Andrew Smith joins Santhera with broad experience in corporate and operational finance in the pharmaceutical and biotech industry, most recently as CFO and COO at Allecra Therapeutics GmbH. Previously, Andrew was CFO of NASDAQ-listed Sucampo Pharmaceuticals Inc., based in the US. During that time, he was involved in a number of capital market transactions in the value of approximately USD 600 million. Prior to that, he held various financial and operations roles focusing on business improvement and transformation where he has gained significant exposure to European and US markets in different organizations with a focus on start-ups, spinoffs and growth. Andrew is a Fellow of the Chartered Institute of Management Accountants and a Chartered Global Management Accountant. He studied business and accounting at Liverpool John Moores University and Durham University Business School.

Dario Eklund, Chief Executive Officer of Santhera, said: “Andrew is a results-driven and entrepreneurial CFO with a very broad financial and operations background. With his proven track record in all aspects of corporate finance both in Europe and the US, the Board of Directors and I believe that Andrew possesses the expertise and leadership capabilities to strategically and effectively run our finance operations, thereby advancing Santhera towards sustainable growth. I extend a warm welcome to Andrew and I am looking forward to working with him.”

“I am excited to join Santhera at the current time where the company expects several near-term inflection points,” said Andrew Smith, designated CFO. “Together with the experienced senior leadership team including the Company’s new CEO and the support by the Board of Directors, I am looking forward to actively contributing to the Company’s strategic growth plans.”

About Santhera

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera is building a Duchenne muscular dystrophy (DMD) product portfolio to treat patients irrespective of causative mutations, disease stage or age. A marketing authorization application for Puldysa® (idebenone) is currently under review by the European Medicines Agency. Santhera has an option to license vamorolone, a first-in-class anti-inflammatory drug candidate with novel mode of action, currently investigated in a pivotal study in patients with DMD to replace standard corticosteroids. The clinical stage pipeline also includes POL6014 to treat cystic fibrosis (CF) and
other neutrophilic pulmonary diseases, as well as omigapil and an exploratory gene therapy approach targeting congenital muscular dystrophies. Santhera out-licensed ex-North American rights to its first approved product, Raxone® (idebenone), for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group. For further information, please visit

Raxone® and Puldysa® are trademarks of Santhera Pharmaceuticals.

For further information please contact: or
Eva Kalias, Head External Communications
Phone: +41 79 875 27 80

Disclaimer / Forward-looking statements

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements. # # #

Santhera Pharmaceuticals Holding AG
Hohenrainstrasse 24, 4133 Pratteln, Switzerland
Phone: +41 61 906 89 50 | Fax: +41 61 906 89 51

Record changed: 2020-02-02


Picture [iito] Männer Ballett 650x100px

More documents for Santhera (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture [iito] [LSE] Business Portal 650x300px

» top